Home Colorectal Cancer Natera to collaborate with MGH on breast cancer trial

Natera to collaborate with MGH on breast cancer trial

59
0

The study will include patients with localized post-menopausal breast cancer with detectable circulating tumor DNA (ctDNA) after surgery, and will assess tumor response to ribociclib treatment in combination with endocrine therapy compared to endocrine therapy alone, the company said. The trial will use Natera’s Signatera ctDNA test to identify eligible study participants.


Related Reading



Copyright © 2020 LabPulse.com

https://www.labpulse.com/index.aspx?sec=log&itemID=801661

This site uses Akismet to reduce spam. Learn how your comment data is processed.